Government will subsidize a range of life-changing drugs from June 1, including chronic lung disease.
More than five hundred thousand people in Australia with chronic lung disease and severe dyspnea, a drug that can change their lives, are on the verge of a sharp drop in prices.
Tambor government included inhaler Trelegy in the drug purchase concession (PBS), an inhaler for patients with moderate to severe obstructive pulmonary disease.
This will mean that patients do not have to pay a high price of 1200 yuan a year, up from a maximum of 39.50 yuan per prescription on Friday.
Patients with preferential certificates pay only 6.4 yuan per prescription.
Health Secretary Greg Hunter (Greg Hunt) says the disease is the second most common cause of avoidable hospitalization in Australia.
It is also a major cause of death and burden of disease after heart disease, stroke and cancer.
" six hundred thousand Australians will have access to drugs that they might not have access to," Hunt told (ABC) on Sunday. "it will have a profound impact on their quality of life."
Starting June 1, Australians with type 2 diabetes can also save about $1700 a year on Trulicity, for less than $40 per prescription.
Australians with ulcerative colitis can also save $15800 a year by getting Simponi, at a low price.
At the same time, about 500 IV-stage transparent cell cancer patients will be able to get low-cost access to Cabometyx, without subsidies, which would cost them about 129800 yuan a year.